Physician profile
Joseph Ehab Zikry
NPI 1366978918
$6,260.68
in general payments reported to CMS, 2019-2025
27 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2021: $106 · 2022: $441 · 2023: $1,058 · 2024: $2,236 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,616.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $781.64 | 2022-2025 | Qulipta, Ubrelvy |
| Regeneron Healthcare Solutions, INC. | $759.85 | 2021-2025 | Dupixent |
| Ucb, INC. | $670.37 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $644.76 | 2023-2025 | Otezla, Otezla, Aimovig |
| Genzyme Corporation | $554.47 | 2023-2025 | |
| Leo Pharma INC. | $432.57 | 2024-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $364.19 | 2024-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $341.14 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $306.18 | 2022-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $267.73 | 2023-2024 | Sotyktu |
| Incyte Corporation | $153.85 | 2023-2025 | Opzelura |
| Pfizer INC. | $143.91 | 2025 | |
| Arcutis Biotherapeutics, INC. | $129.04 | 2023-2025 | Zoryve |
| Exact Sciences Corporation | $115.94 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $97.33 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $79.22 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.86 | 2023-2024 | Jardiance, Cyltezo, Synjardy |
| Sk Life Science, INC. | $69.92 | 2022-2023 | |
| Lundbeck LLC | $55.46 | 2022 | |
| Novo Nordisk INC | $43.07 | 2023-2024 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $30.66 | 2023 | Ongentys, Ingrezza |
| Aimmune Therapeutics, INC. | $30.63 | 2025 | Vowst |
| Merz North America, INC. | $28.60 | 2021 | |
| Botanix Sb INC | $24.84 | 2025 | Sofdra |
| Bayer Healthcare Pharmaceuticals INC. | $23.43 | 2025 | |
| Gilead Sciences, INC. | $22.88 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Zikry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.